References analysis of the Wikipedia article "Bisphosphonate" in the English version

doi.org

Eriksen EF, Díez-Pérez A, Boonen S (January 2014). "Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review". Bone. 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID 24120384.

Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). "Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis". Gynecol. Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID 24063695. S2CID 20163452.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM (2010). "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis". Endocr Pract. 16 (Suppl 3): 1–37. doi:10.4158/ep.16.s3.1. PMC 4876714. PMID 21224201.

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (January 2013). "European guidance for the diagnosis and management of osteoporosis in postmenopausal women". Osteoporos Int. 24 (1): 23–57. doi:10.1007/s00198-012-2074-y. PMC 3587294. PMID 23079689.

Weinstein RS, Roberson PK, Manolagas SC (January 2009). "Giant osteoclast formation and long-term oral bisphosphonate therapy". N. Engl. J. Med. 360 (1): 53–62. doi:10.1056/NEJMoa0802633. PMC 2866022. PMID 19118304.

Russell, R. Graham G. (2011). "Bisphosphonates: The first 40years". Bone. 49 (1): 2–19. doi:10.1016/j.bone.2011.04.022. PMID 21555003.

Allen, CS; Yeung, JH; Vandermeer, B; Homik, J (5 October 2016). "Bisphosphonates for steroid-induced osteoporosis". The Cochrane Database of Systematic Reviews. 2016 (10): CD001347. doi:10.1002/14651858.CD001347.pub2. PMC 6461188. PMID 27706804.

"Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society". Menopause. 17 (1): 25–54, quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID 20061894. S2CID 7980731.

Compston J, Bowring C, Cooper A, et al. (August 2013). "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013". Maturitas. 75 (4): 392–6. doi:10.1016/j.maturitas.2013.05.013. PMID 23810490.

Adler, Robert A; El-Hajj Fuleihan, Ghada; Bauer, Douglas C; Camacho, Pauline M; Clarke, Bart L; Clines, Gregory A; Compston, Juliet E; Drake, Matthew T; Edwards, Beatrice J; Favus, Murray J; Greenspan, Susan L; McKinney, Ross; Pignolo, Robert J; Sellmeyer, Deborah E (January 2016). "Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research". Journal of Bone and Mineral Research. 31 (1): 16–35. doi:10.1002/jbmr.2708. PMC 4906542. PMID 26350171.

Zhu M, Liang R, Pan LH, et al. (February 2013). "Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials". Pain Med. 14 (2): 257–64. doi:10.1111/pme.12016. PMID 23279447.

O'Carrigan, Brent; Wong, Matthew Hf; Willson, Melina L.; Stockler, Martin R.; Pavlakis, Nick; Goodwin, Annabel (2017). "Bisphosphonates and other bone agents for breast cancer". The Cochrane Database of Systematic Reviews. 10 (11): CD003474. doi:10.1002/14651858.CD003474.pub4. ISSN 1469-493X. PMC 6485886. PMID 29082518.

Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME (November 2012). "Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis". Support Care Cancer. 20 (11): 2985–98. doi:10.1007/s00520-012-1563-z. PMC 3691019. PMID 22956190.

Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B (2017). "Bisphosphonates in multiple myeloma: a network meta-analysis". Cochrane Database Syst Rev. 2017 (12): CD003188. doi:10.1002/14651858.CD003188.pub4. PMC 6486151. PMID 29253322.

Ben-Aharon I, Vidal L, Rizel S, et al. (2013). "Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis". PLOS ONE. 8 (8): e70044. Bibcode:2013PLoSO...870044B. doi:10.1371/journal.pone.0070044. PMC 3753308. PMID 23990894.

Zhu J, Zheng Y, Zhou Z (June 2013). "Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis". Eur. J. Cancer. 49 (9): 2086–92. doi:10.1016/j.ejca.2013.01.021. PMID 23452992.

Van Acker, HH; Anguille, S; Willemen, Y; Smits, EL; Van Tendeloo, VF (23 November 2015). "Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials". Pharmacology & Therapeutics. 158: 24–40. doi:10.1016/j.pharmthera.2015.11.008. PMID 26617219.

Pontell D (July 2008). "A clinical approach to complex regional pain syndrome". Clinics in Podiatric Medicine and Surgery. 25 (3): 361–80, vi. doi:10.1016/j.cpm.2008.02.011. PMID 18486850.

Thompson J (2023). "Association between Bisphosphonate use and COVID-19 related outcomes". eLife. 12: e79548. doi:10.7554/eLife.79548. PMC 10691801. PMID 37534876.

Muzaffar-Ur-Rehman M (May 2025). "In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition". Journal of Molecular Graphics and Modelling. 136: 108939. doi:10.1016/j.jmgm.2024.108939. PMID 39799876.

Shapiro JR, Sponsellor PD (December 2009). "Osteogenesis imperfecta: questions and answers". Current Opinion in Pediatrics. 21 (6): 709–16. doi:10.1097/MOP.0b013e328332c68f. PMID 19907330. S2CID 205834462.

Woo S, Hellstein J, Kalmar J (2006). "Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws". Ann Intern Med. 144 (10): 753–61. doi:10.7326/0003-4819-144-10-200605160-00009. PMID 16702591. S2CID 53091343.

Wysowski D, Chang J (2005). "Alendronate and risedronate: reports of severe bone, joint, and muscle pain". Arch Intern Med. 165 (3): 346–7. doi:10.1001/archinte.165.3.346-b. PMID 15710802.

Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, Homel P, Borer JS, Lichstein E (June 1, 2014). "Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates". American Journal of Cardiology. 113 (11): 1815–1821. doi:10.1016/j.amjcard.2014.03.008. PMID 24837258.

Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, Aikat S (October 2013). "Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis". Chest. 144 (4): 1131–1322. doi:10.1378/chest.13-0675. PMID 23722644.

Shane E (May 2010). "Evolving data about subtrochanteric fractures and bisphosphonates". N. Engl. J. Med. 362 (19): 1825–7. doi:10.1056/NEJMe1003064. PMID 20335574.

Lenart BA, Lorich DG, Lane JM (March 2008). "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate". N. Engl. J. Med. 358 (12): 1304–6. doi:10.1056/NEJMc0707493. PMID 18354114.

Arkan S Sayed-Noor; Bakir K Kadum; Göran O Sjödén (31 March 2010). "Bisphosphonate-induced femoral fragility fractures: What do we know?". Orthopedic Research and Reviews. 2 (1): 27–34. doi:10.2147/orr.s7521.

Andrici J, Tio M, Eslick GD (October 2012). "Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer". Aliment. Pharmacol. Ther. 36 (8): 708–16. doi:10.1111/apt.12041. PMID 22966908. S2CID 5271005.

Sun K, Liu JM, Sun HX, Lu N, Ning G (January 2013). "Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies". Osteoporos Int. 24 (1): 279–86. doi:10.1007/s00198-012-2158-8. PMID 23052941. S2CID 12625687.

Oh YH, Yoon C, Park SM (October 2012). "Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies". World J. Gastroenterol. 18 (40): 5779–88. doi:10.3748/wjg.v18.i40.5779. PMC 3484348. PMID 23155320.

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (May 2008). "Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells". Bone. 42 (5): 848–860. doi:10.1016/j.bone.2007.12.225. PMID 18325866.

Frith J, Mönkkönen J, Blackburn G, Russell R, Rogers M (1997). "Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro". J Bone Miner Res. 12 (9): 1358–67. doi:10.1359/jbmr.1997.12.9.1358. PMID 9286751.

van Beek E, Cohen L, Leroy I, Ebetino F, Löwik C, Papapoulos S (November 2003). "Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates". Bone. 33 (5): 805–11. doi:10.1016/j.bone.2003.07.007. PMID 14623056.

Wiemer, AJ; Wiemer, DF; Hohl, RJ (December 2011). "Geranylgeranyl diphosphate synthase: an emerging therapeutic target". Clinical Pharmacology and Therapeutics. 90 (6): 804–12. doi:10.1038/clpt.2011.215. PMID 22048229. S2CID 27913789.

Van Beek E, Löwik C, van der Pluijm G, Papapoulos S (1999). "The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates". J Bone Miner Res. 14 (5): 722–9. doi:10.1359/jbmr.1999.14.5.722. PMID 10320520. S2CID 20316713.

Uzzan, B; et al. (2007). "Effects of statins on bone mineral density: a meta-analysis of clinical studies". Bone. 40 (6): 1581–7. doi:10.1016/j.bone.2007.02.019. PMID 17409043.

Fleisch H (2002). "Development of bisphosphonates". Breast Cancer Res. 4 (1): 30–4. doi:10.1186/bcr414. PMC 138713. PMID 11879557.

nih.gov

pubmed.ncbi.nlm.nih.gov

Gauthier, K; Bai, A; Perras, C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (February 2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms". Rapid Response Report: Systematic Review. PMID 24278999.

Russell, R. Graham G. (2011). "Bisphosphonates: The first 40years". Bone. 49 (1): 2–19. doi:10.1016/j.bone.2011.04.022. PMID 21555003.

Hauk L (August 2013). "ACOG releases practice bulletin on osteoporosis". Am Fam Physician. 88 (4): 269–75. PMID 23944732.

Pontell D (July 2008). "A clinical approach to complex regional pain syndrome". Clinics in Podiatric Medicine and Surgery. 25 (3): 361–80, vi. doi:10.1016/j.cpm.2008.02.011. PMID 18486850.

Thompson J (2023). "Association between Bisphosphonate use and COVID-19 related outcomes". eLife. 12: e79548. doi:10.7554/eLife.79548. PMC 10691801. PMID 37534876.

Brookler K (2008). "Medical treatment of otosclerosis: rationale for use of bisphosphonates". Int Tinnitus J. 14 (2): 92–6. PMID 19205157.

Wysowski D, Chang J (2005). "Alendronate and risedronate: reports of severe bone, joint, and muscle pain". Arch Intern Med. 165 (3): 346–7. doi:10.1001/archinte.165.3.346-b. PMID 15710802.

Shane E (May 2010). "Evolving data about subtrochanteric fractures and bisphosphonates". N. Engl. J. Med. 362 (19): 1825–7. doi:10.1056/NEJMe1003064. PMID 20335574.

Uzzan, B; et al. (2007). "Effects of statins on bone mineral density: a meta-analysis of clinical studies". Bone. 40 (6): 1581–7. doi:10.1016/j.bone.2007.02.019. PMID 17409043.

Fleisch H (2002). "Development of bisphosphonates". Breast Cancer Res. 4 (1): 30–4. doi:10.1186/bcr414. PMC 138713. PMID 11879557.

ncbi.nlm.nih.gov

nos.org.uk

National Osteoporosis Society. "Drug Treatment". U.K. National Osteoporosis Society. Archived from the original on 6 November 2012. Retrieved 7 August 2012.

semanticscholar.org

api.semanticscholar.org

web.archive.org

worldcat.org

search.worldcat.org

Bisphosphonate (English Wikipedia)

doi.org

drugs.com

fda.gov

harvard.edu

ui.adsabs.harvard.edu

mhra.gov.uk